Page 123 - 《中国药房》2024年22期

[ 7 ] ROSENBERG J E，PARK S H，KOZLOV V，et al. Dur‐ tive，open-label，randomized，phase Ⅲ study of two dose-
valumab plus olaparib in previously untreated，platinumi- dense regimens MVAC versus gemcitabine/cisplatin in pa‐
neligible patients with metastatic urothelial carcinoma：a tients with inoperable，metastatic or relapsed urothelial
multicenter，randomized，phase Ⅱ trial（BAYOU）[J]. J cancer：a Hellenic Cooperative Oncology Group study
Clin Oncol，2023，41（1）：43-53. （HE 16/03）[J]. Ann Oncol，2013，24（4）：1011-1017.
[ 8 ] O’DONNELL P H，MILOWSKY M I，PETRYLAK D P， [15] PFISTER C，GRAVIS G，FLECHON A，et al. Periopera‐
et al. Enfortumab vedotin with or without pembrolizumab tive dose-dense methotrexate，vinblastine，doxorubicin，
in cisplatin-ineligible patients with previously untreated and cisplatin in muscle-invasive bladder cancer（VESPER）：
locally advanced or metastatic urothelial cancer[J]. J Clin survival endpoints at 5 years in an open-label，randomised，
Oncol，2023，41（25）：4107-4117. phase 3 study[J]. Lancet Oncol，2024，25（2）：255-264.
[ 9 ] VAN DER HEIJDEN M S，SONPAVDE G，POWLES T， [16] METRANGOLO V，ENGELHOLM L H. Antibody-drug
et al. Nivolumab plus gemcitabine-cisplatin in advanced conjugates：the dynamic evolution from conventional to
urothelial carcinoma[J]. N Engl J Med，2023，389（19）： next-generation constructs[J]. Cancers（Basel），2024，16
1778-1789. （2）：447.
[10] CULINE S，FLÉCHON A，GRAVIS G，et al. Dose-dense [17] BARDIA A，MAYER I A，VAHDAT L T，et al. Sacitu‐
methotrexate，vinblastine，doxorubicin，and cisplatin with zumab govitecan-hziy in refractory metastatic triple-
or without panitumumab in patients with advanced urothe‐ negative breast cancer[J]. N Engl J Med，2019，380（8）：
lial carcinoma：multicenter，randomized，French Unican‐ 741-751.
cer GETUG/AFU 19 study[J]. Clin Genitourin Cancer， [18] PENG Z，LIU T S，WEI J，et al. Efficacy and safety of a
2021，19（4）：e216-e222. novel anti-HER2 therapeutic antibody RC48 in patients
[11] POWLES T，CSÖSZI T，ÖZGÜROĞLU M，et al. Pembro‐ with HER2-overexpressing，locally advanced or meta‐
lizumab alone or combined with chemotherapy versus che‐ static gastric or gastroesophageal junction cancer：a single-
motherapy as first-line therapy for advanced urothelial car‐ arm phase Ⅱ study[J]. Cancer Commun，2021，41（11）：
cinoma（KEYNOTE-361）：a randomised，open-label， 1173-1182.
phase 3 trial[J]. Lancet Oncol，2021，22（7）：931-945. [19] TAGAWA S T，BALAR A V，PETRYLAK D P，et al.
[12] POWLES T B，PEREZ VALDERRAMA B，GUPTA S，et TROPHY-U-01：a phase Ⅱ open-label study of sacitu‐
al. LBA6 EV-302/KEYNOTE-A39：open-label，rando- zumab govitecan in patients with metastatic urothelial car‐
mized phase Ⅲ study of enfortumab vedotin in combination cinoma progressing after platinum-based chemotherapy
with pembrolizumab（EV+P）vs. chemotherapy（Chemo） and checkpoint inhibitors[J]. J Clin Oncol，2021，39（22）：
in previously untreated locally advanced metastatic urothe‐ 2474-2485.
lial carcinoma（LA/mUC）[J]. Ann Oncol，2023，34：S1340. [20] SHENG X N，WANG L，HE Z S，et al. Efficacy and
[13] POWLES T，VAN DER HEIJDEN M S，CASTELLANO safety of disitamab vedotin in patients with human epider‐
D，et al. Durvalumab alone and durvalumab plus tremeli- mal growth factor receptor 2-positive locally advanced or
mumab versus chemotherapy in previously untreated pa‐ metastatic urothelial carcinoma：a combined analysis of
tients with unresectable，locally advanced or metastatic two phase Ⅱ clinical trials[J]. J Clin Oncol，2024，42
urothelial carcinoma（DANUBE）：a randomised，open- （12）：1391-1402.
label，multicentre，phase 3 trial[J]. Lancet Oncol，2020，21 （收稿日期：2024-03-19 修回日期：2024-07-28）
（12）：1574-1588. （编辑：刘明伟）
[14] BAMIAS A，DAFNI U，KARADIMOU A，et al. Prospec‐

中国药房 2024年第35卷第22期 China Pharmacy 2024 Vol. 35 No. 22 · 2821 ·